Clinical Trials
18 trialsNCT00265798 2026-04-28
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01871766 2026-04-24
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02050919 2022-03-21
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00880542 2020-08-10
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT00621686 2018-05-08
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00445588 2016-04-27
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00238121 2015-11-20
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00837148 2015-11-20
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02599090 2015-11-06
Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01804374 2015-06-17
SERIO
Italian Sarcoma Group
Phase 2 Completed
NCT00245102 2014-05-23
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00217620 2014-05-15
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00330421 2014-04-30
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
National Cancer Institute (NCI)
Phase 2 Completed
NCT00597493 2013-06-24
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
Duke University
Phase 2 Completed
NCT00889057 2013-03-28
Sorafenib in Relapsed High Grade Osteosarcoma
Italian Sarcoma Group
Phase 2 Completed
NCT01091207 2012-01-20
Sorafenib for Imatinib/Sunitinib-failed GIST
Samsung Medical Center
Phase 2 Completed
NCT00406601 2010-09-02
BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas
Istituto Clinico Humanitas
Phase 2 Completed
NCT00874874 2009-12-24
Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown